Sweden · Delayed Price · Currency is SEK Cinclus Pharma Holding AB Earnings Call Transcripts
Fiscal Year 2026
-
Linaprazan glurate, a next-generation P-CAB for severe erosive GERD, is in phase III trials with top-line results expected in Q4. The drug aims for best-in-class acid control and symptom relief, targeting a large, underserved patient population and potential approval by 2030.
-
Lead asset linaprazan glurate advanced toward pivotal phase III results, with strong regulatory alignment and commercial launches in China. Q1 2026 saw increased R&D spending, improved cash flow, and new financing to support ongoing trials and future growth.
Fiscal Year 2025
-
Lead candidate linaprazan glurate advances in phase III with strong global partnerships and regulatory progress. Q4 saw increased R&D investment, solid cash reserves, and rising licensing revenues. Market trends and clinical differentiation support significant commercial potential.
-
Linaprazan glurate, a next-generation PCAB, is positioned to address major unmet needs in severe erosive GERD, offering rapid, superior acid control and targeting a large, dynamic market. Strategic focus on gastroenterologists and strong clinical differentiation are expected to drive adoption.
-
Phase III trial for linaprazan glurate is underway with strong early recruitment and robust financial resources extending into 2027. The product demonstrates superior acid control and healing rates, supporting best-in-class potential as PCABs gain global market share.
-
Linaprazan glurate, a next-generation PCAB, is in Phase III trials targeting severe GERD patients with unmet needs, aiming for premium pricing and specialist market focus. Strong IP, a major European partnership, and a U.S. launch planned for 2029-2030 underpin the strategy.
-
Secured a EUR 220 million Zentiva partnership for Linaprazan glurate in Europe, with phase III trial preparations complete and imminent start. Cash position remains strong at SEK 589 million, and U.S. commercialization rights are retained for future value creation.
-
A strategic partnership with Zentiva secures up to EUR 220 million for linaprazan glurate's European commercialization, with strong royalty terms and a 10-year exclusivity. Zentiva's pan-European reach and specialty pharma focus support targeting severe GERD patients and may accelerate clinical development.
-
Lead asset linaprazan glurate advances to Phase III after strong Phase II results, targeting severe eGERD with best-in-class potential and robust patent protection. Cash reserves support operations through 2026, with premium pricing and dynamic market opportunities anticipated.
Fiscal Year 2024
-
PCABs are rapidly gaining market share globally, with linaprazan glurate now approved in China and pivotal Phase III trials set for the U.S. and Europe. Financials remain strong after a major share issue, supporting operations through key 2026 milestones.
-
Development of linaprazan glarate advances with phase III trial preparations on schedule and strong IP protection extending beyond 2040. Cash reserves remain robust post-IPO, with further financing planned after key clinical milestones.
-
Strong cash position after a SEK 750 million IPO supports phase III development of a next-gen P-CAB for severe eGERD, with first patient expected in 2025 and key readouts in 2026. Patent protection extends to 2042, and China approval could bring milestone payments by year-end.